Intellia Therapeutics Inc (NASDAQ:NTLA) has a beta value of 2.17 and has seen 1.27 million shares traded in the recent trading session. The company, currently valued at $751.28M, closed the recent trade at $7.26 per share which meant it lost -$0.81 on the day or -10.07% during that session. The NTLA stock price is -288.15% off its 52-week high price of $28.18 and -10.61% below the 52-week low of $8.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.21 million shares traded. The 3-month trading volume is 3.25 million shares.
The consensus among analysts is that Intellia Therapeutics Inc (NTLA) is Buy stock at the moment, with a recommendation rating of 1.71. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 13 have rated it as a Hold, with 13 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.26.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Sporting -10.07% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NTLA stock price touched $7.26 or saw a rise of 22.44%. Year-to-date, Intellia Therapeutics Inc shares have moved -37.76%, while the 5-day performance has seen it change -22.05%. Over the past 30 days, the shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have changed -28.07%. Short interest in the company has seen 26.69 million shares shorted with days to cover at 7.06.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 67.0% from the levels at last check today.. The projected low price target is $9.0 while the price target rests at a high of $60.0. In that case, then, we find that the latest price level in today’s session is -726.45% off the targeted high while a plunge would see the stock gain -23.97% from the levels at last check today..
Intellia Therapeutics Inc (NTLA) estimates and forecasts
The company’s shares have lost -64.72% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -17.91%.
20 analysts offering their estimates for the company have set an average revenue estimate of 11.39M for the current quarter. 20 have an estimated revenue figure of 11.37M for the next ending quarter. Year-ago sales stood 28.93M and 6.96M respectively for this quarter and the next, and analysts expect sales will shrink by -60.65% for the current quarter and -17.91% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -20.04% over the past 5 years. Earnings growth for 2025 is a modest 11.04% while over the next 5 years, the company’s earnings are expected to increase by 25.47%.
NTLA Dividends
Intellia Therapeutics Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Insiders own 5.05% of the company shares, while shares held by institutions stand at 91.72% with a share float percentage of 96.60%. Investors are also buoyed by the number of investors in a company, with Intellia Therapeutics Inc having a total of 417.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares worth more than $259.51 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.9575% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 9.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $214.79 million and represent 9.897% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . As of Feb 28, 2025 , the former fund manager holds about 8.42% shares in the company for having 8.72 shares of worth $62.94 million while later fund manager owns 3.09 shares of worth $22.27 million as of Feb 28, 2025 , which makes it owner of about 2.98% of company’s outstanding stock.
